Sector
PharmaceuticalsOpen
₹2,012Prev. Close
₹2,030.7Turnover(Lac.)
₹18,227.71Day's High
₹2,012Day's Low
₹1,956.752 Week's High
₹2,284.852 Week's Low
₹1,275.5Book Value
₹880.02Face Value
₹1Mkt Cap (₹ Cr.)
55,641.53P/E
30.59EPS
66.4Divi. Yield
0.12Here are some of the stocks that may see significant price movement today: Polycab India, Tata Steel, Dalmia Bharat, etc.
Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Rail Vikas Nigam, Birla Corp, etc.
At around 2.19 PM, Glenmark Pharma was trading 2.97% higher at ₹2,112.90 per piece, against the previous close of ₹2,051.90 on NSE.
Operating performance was slightly weaker, with EBITDA dipping 1.4% to ₹580 crore from ₹588.2 crore.
Here are some of the stocks that may see significant price movement today: Glenmark Pharmaceuticals, Vedanta, Inox Wind, etc.
Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|---|
Equity Capital | 28.22 | 28.22 | 28.22 | 28.22 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 24,475.74 | 22,942.4 | 17,849.25 | 16,710.37 |
Net Worth | 24,503.96 | 22,970.62 | 17,877.47 | 16,738.59 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 7,567.93 | 6,712.63 | 6,403.23 | 7,989.23 |
yoy growth (%) | 12.74 | 4.83 | -19.85 | 30.64 |
Raw materials | -2,999.45 | -2,665.99 | -2,378.59 | -2,425.49 |
As % of sales | 39.63 | 39.71 | 37.14 | 30.35 |
Employee costs | -1,107.39 | -1,072.32 | -1,021.92 | -914.47 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 1,869.86 | 1,516.09 | 1,218.82 | 2,789.34 |
Depreciation | -150.81 | -138.53 | -118.2 | -104.93 |
Tax paid | -294.31 | -180.09 | -204.47 | -412.28 |
Working capital | 463.74 | -1,507.52 | -180.36 | 1,492.86 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 12.74 | 4.83 | -19.85 | 30.64 |
Op profit growth | 44.93 | -3.21 | -53.51 | 64.2 |
EBIT growth | 20.49 | 25.73 | -52.08 | 65.02 |
Net profit growth | 21.77 | 33.53 | -52.61 | 44.21 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 13,145.84 | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 13,145.84 | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 |
Other Operating Income | 175.9 | 177.64 | 151.3 | 130.71 | 137.9 |
Other Income | 113.72 | 1,237.32 | 755.86 | 166.67 | 94.76 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,586.7 | 78.42 | 3,90,611.73 | 753.53 | 0.98 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 5,689.5 | 67.03 | 1,56,589.3 | 557 | 0.51 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,499.4 | 23.61 | 1,21,954.71 | 1,303.13 | 1.06 | 4,501.66 | 397.38 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,561 | 60.14 | 1,19,555.56 | 551 | 0.17 | 2,567 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,253.1 | 15.44 | 1,06,396.56 | 2,961.2 | 0.63 | 7,788.7 | 345.74 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman / Executive Director / M D / Promoter
Glenn Saldanha
ED / WTD / Promoter
Cheryl Pinto
ED / President / Global CFO
Anurag Mantri
Non Executive Director
B E Saldanha
Independent Non Exe. Director
Sona Saira Ramasastry
Independent Non Exe. Director
Dipankar Bhattacharjee
Independent Non Exe. Director
V R Iyer
Independent Non Exe. Director
Pradeep Kumar Sinha
Company Sec. & Compli. Officer
Harish Kuber
B/2 Mahalaxmi Chambers,
22 Bhulabhai Desai Road,
Maharashtra - 400026
Tel: 91-22-40189999
Website: http://www.glenmarkpharma.com
Email: complianceofficer@glenmarkpharma.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological enti...
Read More
Reports by Glenmark Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.